HC Wainwright Has Negative Outlook for ENLV FY2025 Earnings

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) – Analysts at HC Wainwright dropped their FY2025 earnings per share (EPS) estimates for Enlivex Therapeutics in a report issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($0.59) for the year, down from their previous forecast of ($0.58). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Enlivex Therapeutics’ current full-year earnings is ($0.70) per share.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a research report on Monday, March 3rd.

Enlivex Therapeutics Trading Down 3.8 %

NASDAQ ENLV opened at $1.01 on Wednesday. The stock has a fifty day simple moving average of $1.10 and a 200-day simple moving average of $1.24. The stock has a market cap of $21.62 million, a PE ratio of -1.03 and a beta of 1.11. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.59.

Institutional Trading of Enlivex Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC acquired a new stake in shares of Enlivex Therapeutics in the fourth quarter valued at $742,000. Renaissance Technologies LLC grew its position in Enlivex Therapeutics by 112.6% in the 4th quarter. Renaissance Technologies LLC now owns 158,992 shares of the company’s stock valued at $186,000 after acquiring an additional 84,203 shares in the last quarter. Finally, Two Sigma Securities LLC acquired a new position in Enlivex Therapeutics in the 4th quarter valued at about $26,000. Hedge funds and other institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.